{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:14:46Z","timestamp":1791213286851,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"am","delay-in-days":347,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience & Biobehavioral Reviews"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.neubiorev.2022.104856","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T11:59:54Z","timestamp":1662465594000},"page":"104856","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Exploring the link between GBA1 mutations and Dementia with Lewy bodies, A mini-review"],"prefix":"10.1016","volume":"141","author":[{"given":"Sinead","family":"Gaubert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Hourregue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Mouton-Liger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9rine","family":"Millot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Amar-Bouaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag","family":"Aarsland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Hugon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Paquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neubiorev.2022.104856_bib1","unstructured":"Assistance Publique - H\u00f4pitaux de Paris. Exploration of Glucocerebrosidase Activity to Identify a Subpopulation Eligible for a Therapeutic Trial in Dementia With Lewy Bodies. clinicaltrials.gov; 2022. Accessed May 3, 2022. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05304195\u3009."},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104856_bib2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bcmd.2005.07.005","article-title":"Hematologically important mutations: Gaucher disease","volume":"35","author":"Beutler","year":"2005","journal-title":"Blood Cells Mol. Dis."},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104856_bib3","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/WAD.0000000000000283","article-title":"Distinguishing dementia with lewy bodies from Alzheimer disease: what is the influence of the GBA genotype in Ashkenazi Jews","volume":"33","author":"Bregman","year":"2019","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.neubiorev.2022.104856_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.562522","article-title":"GBA-associated synucleinopathies: prime candidates for alpha-synuclein targeting compounds","volume":"8","author":"Brockmann","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"5","key":"10.1016\/j.neubiorev.2022.104856_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/archneurol.2009.54","article-title":"Association of glucocerebrosidase mutations with dementia with Lewy bodies","volume":"66","author":"Clark","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neubiorev.2022.104856_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125204","article-title":"Gene-wise association of variants in four lysosomal storage disorder genes in neuropathologically confirmed Lewy body disease","volume":"10","author":"Clark","year":"2015","journal-title":"PLOS One"},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104856_bib7","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ana.22400","article-title":"Acid \u03b2-glucosidase mutants linked to gaucher disease, parkinson disease, and lewy body dementia alter \u03b1-synuclein processing","volume":"69","author":"Cullen","year":"2011","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104856_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13195-017-0288-0","article-title":"Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort","volume":"9","author":"Dufouil","year":"2017","journal-title":"Alzheimers Res Ther."},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104856_bib9","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.parkreldis.2008.08.004","article-title":"Glucosidase-beta variations and Lewy body disorders","volume":"15","author":"Farrer","year":"2009","journal-title":"Park. Relat. Disord."},{"issue":"7","key":"10.1016\/j.neubiorev.2022.104856_bib10","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/mds.26593","article-title":"GBA mutations are associated with earlier onset and male sex in dementia with Lewy bodies: GBA mutations precipitate DLB onset","volume":"31","author":"G\u00e1mez-Valero","year":"2016","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.neubiorev.2022.104856_bib11","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1212\/01.wnl.0000230215.41296.18","article-title":"Glucocerebrosidase mutations are an important risk factor for Lewy body disorders","volume":"67","author":"Goker-Alpan","year":"2006","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.neubiorev.2022.104856_bib12","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00401-010-0741-7","article-title":"Glucocerebrosidase is present in \u03b1-synuclein inclusions in Lewy body disorders","volume":"120","author":"Goker-Alpan","year":"2010","journal-title":"Acta Neuropathol."},{"issue":"10","key":"10.1016\/j.neubiorev.2022.104856_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/archneur.65.10.1353","article-title":"The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations","volume":"65","author":"Goker-Alpan","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neubiorev.2022.104856_bib14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.nbd.2018.09.015","article-title":"Path mediation analysis reveals GBA impacts Lewy body disease status by increasing \u03b1-synuclein levels","volume":"121","author":"G\u00fcndner","year":"2019","journal-title":"Neurobiol. Dis."},{"issue":"7","key":"10.1016\/j.neubiorev.2022.104856_bib15","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jalz.2018.01.004","article-title":"Plasma amyloid levels within the Alzheimer\u2019s process and correlations with central biomarkers","volume":"14","author":"Hanon","year":"2018","journal-title":"Alzheimers Dement J."},{"key":"10.1016\/j.neubiorev.2022.104856_bib16","unstructured":"Helse Fonna, 2021. A Clinical Trial to Demonstrate Clinical Efficacy on Cognitive, Neuropsychiatric and Functional Outcomes of Ambroxol in New and Early Patients With Prodromal and Mild Dementia With Lewy bodies (Clinical Trial Registration No. NCT04588285). clinicaltrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04588285."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104856_bib17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1474-4422(16)30291-5","article-title":"Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis","volume":"16","author":"Irwin","year":"2017","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.neubiorev.2022.104856_bib18","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/hmg\/ddy105","article-title":"Acid ceramidase inhibition ameliorates \u03b1-synuclein accumulation upon loss of GBA1 function","volume":"27","author":"Kim","year":"2018","journal-title":"Hum. Mol. Genet."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104856_bib19","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1471-4159.2012.07879.x","article-title":"Glucocerebrosidase mutations alter the endoplasmic reticulum and lysosomes in Lewy body disease: GCase mutations in Lewy body disease","volume":"123","author":"Kurzawa-Akanbi","year":"2012","journal-title":"J. Neurochem"},{"key":"10.1016\/j.neubiorev.2022.104856_bib20","doi-asserted-by":"crossref","DOI":"10.1007\/s00401-021-02367-3","article-title":"Altered ceramide metabolism is a feature in the extracellular vesicle-mediated spread of alpha-synuclein in Lewy body disorders","author":"Kurzawa-Akanbi","year":"2021","journal-title":"Acta Neuropathol."},{"issue":"7","key":"10.1016\/j.neubiorev.2022.104856_bib21","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/mds.27731","article-title":"Dementia with lewy bodies: GBA1 mutations are associated with cerebrospinal fluid alpha\u2010synuclein profile","volume":"34","author":"Lerche","year":"2019","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104856_bib22","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s10571-015-0176-8","article-title":"Gaucher-associated Parkinsonism","volume":"35","author":"Li","year":"2015","journal-title":"Cell Mol. Neurobiol."},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104856_bib23","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/archneurol.2007.68","article-title":"Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders","volume":"65","author":"Mata","year":"2008","journal-title":"Arch. Neurol."},{"issue":"29","key":"10.1016\/j.neubiorev.2022.104856_bib24","doi-asserted-by":"crossref","first-page":"7693","DOI":"10.1523\/JNEUROSCI.0628-16.2016","article-title":"Activation of -glucocerebrosidase reduces pathological -synuclein and restores lysosomal function in Parkinson\u2019s patient midbrain neurons","volume":"36","author":"Mazzulli","year":"2016","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104856_bib25","doi-asserted-by":"crossref","first-page":"333","DOI":"10.31887\/DCNS.2004.6.3\/imckeith","article-title":"Dementia with Lewy bodies","volume":"6","author":"McKeith","year":"2004","journal-title":"Dialog-. Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104856_bib26","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.neubiorev.2022.104856_bib27","first-page":"339","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104856_bib28","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1007\/s12035-018-1090-0","article-title":"Characterization of brain lysosomal activities in GBA-related and sporadic Parkinson\u2019s disease and dementia with Lewy bodies","volume":"56","author":"Moors","year":"2019","journal-title":"Mol. Neurobiol."},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104856_bib29","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2013.1925","article-title":"A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies","volume":"70","author":"Nalls","year":"2013","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104856_bib30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.parkreldis.2010.09.009","article-title":"Glucocerebrosidase mutations in diffuse Lewy body disease","volume":"17","author":"Nishioka","year":"2011","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neubiorev.2022.104856_bib31","unstructured":"Oxford Centre for Evidence-Based Medicine, 2009. Available online: \u3008https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence\u3009."},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104856_bib32","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.pneurobio.2011.09.005","article-title":"The Parkinson progression marker initiative (PPMI)","volume":"95","author":"Parkinson Progression Marker Initiative","year":"2011","journal-title":"Prog. Neurobiol."},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104856_bib33","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.nbd.2009.03.002","article-title":"Cerebrospinal fluid \u03b2-glucocerebrosidase activity is reduced in Dementia with Lewy bodies","volume":"34","author":"Parnetti","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neubiorev.2022.104856_bib34","unstructured":"Pasternak, S., 2022. Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia (Clinical Trial Registration No. NCT04405596). clinicaltrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04405596."},{"key":"10.1016\/j.neubiorev.2022.104856_bib35","unstructured":"Prevail Therapeutics, 2022. A Phase 1\/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients With Parkinson\u2019s Disease With at Least One GBA1 Mutation (PROPEL) (Clinical Trial Registration No. NCT04127578). clinicaltrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04127578."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104856_bib36","doi-asserted-by":"crossref","first-page":"208","DOI":"10.14336\/AD.2017.0505","article-title":"Glucocerebrosidase mRNA is diminished in brain of Lewy body diseases and changes with disease progression in blood","volume":"9","author":"Perez-Roca","year":"2018","journal-title":"Aging Dis."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104856_bib37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.14283\/jpad.2019.46","article-title":"The European prevention of Alzheimer\u2019s Dementia (EPAD) longitudinal cohort study: baseline data release V500.0","volume":"7","author":"Ritchie","year":"2020","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.neubiorev.2022.104856_bib38","unstructured":"Sanofi, 2022. Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ\/SAR402671 in Patients With Early-stage Parkinson\u2019s Disease Carrying a GBA Mutation or Other Pre-specified Variant (Clinical Trial Registration No. NCT02906020). clinicaltrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02906020."},{"issue":"10","key":"10.1016\/j.neubiorev.2022.104856_bib39","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1073\/pnas.1616152114","article-title":"Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models","volume":"114","author":"Sardi","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104856_bib40","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/mds.24045","article-title":"Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson\u2019s disease course","volume":"27","author":"Set\u00f3-Salvia","year":"2012","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.neubiorev.2022.104856_bib41","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jamaneurol.2016.1593","article-title":"High frequency of GBA gene mutations in dementia With Lewy bodies among Ashkenazi Jews","volume":"73","author":"Shiner","year":"2016","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104856_bib42","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3233\/JAD-201295","article-title":"The effect of GBA mutations and APOE polymorphisms on dementia with Lewy bodies in Ashkenazi Jews","volume":"80","author":"Shiner","year":"2021","journal-title":"J. Alzheimers Dis."},{"issue":"17","key":"10.1016\/j.neubiorev.2022.104856_bib43","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multi-center analysis of glucocerebrosidase mutations in Parkinson disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104856_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18020441","article-title":"A review of Gaucher disease pathophysiology, clinical presentation and treatments","volume":"18","author":"Stirnemann","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104856_bib45","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000000523","article-title":"The SPID-GBA study: sex distribution, penetrance, incidence, and dementia in GBA-PD","volume":"6","author":"Straniero","year":"2020","journal-title":"Neurol. Genet"},{"key":"10.1016\/j.neubiorev.2022.104856_bib46","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.parkreldis.2018.05.009","article-title":"Parkinson\u2019s disease phenotype is influenced by the severity of the mutations in the GBA gene","volume":"55","author":"Thaler","year":"2018","journal-title":"Park. Relat. Disord."},{"issue":"19","key":"10.1016\/j.neubiorev.2022.104856_bib47","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1212\/WNL.0b013e3182735e9a","article-title":"GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology","volume":"79","author":"Tsuang","year":"2012","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104856_bib48","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1007\/s12035-021-02688-0","article-title":"Impaired sphingolipid hydrolase activities in dementia with lewy bodies and multiple system atrophy","volume":"59","author":"Usenko","year":"2022","journal-title":"Mol. Neurobiol."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104856_bib49","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3233\/JAD-210365","article-title":"Genetics contributes to concomitant pathology and clinical presentation in dementia with Lewy bodies","volume":"83","author":"van der Lee","year":"2021","journal-title":"J. Alzheimers Dis."},{"issue":"7","key":"10.1016\/j.neubiorev.2022.104856_bib50","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jalz.2015.05.007","article-title":"Introduction to special issue: overview of Alzheimer\u2019s disease neuroimaging initiative","volume":"11","author":"Weiner","year":"2015","journal-title":"Alzheimers Dement J."}],"container-title":["Neuroscience & Biobehavioral Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763422003451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763422003451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:29:16Z","timestamp":1758968956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149763422003451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":50,"alternative-id":["S0149763422003451"],"URL":"https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104856","relation":{},"ISSN":["0149-7634"],"issn-type":[{"value":"0149-7634","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the link between GBA1 mutations and Dementia with Lewy bodies, A mini-review","name":"articletitle","label":"Article Title"},{"value":"Neuroscience & Biobehavioral Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104856","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104856"}}